BioSpace News Archive

Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ended June 30, 2021 and provided an operating forecast and program updates.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 5th, 2021.

Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo) today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer’s disease called ICARE AD-US, at the Alzheimer’s Association International Conference (AAIC), being held both virtually and in Denver, Colo. from July 26 – 30, 2021

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, 2021, at 8:30 a.m. ET.

Dyadic International, Inc. announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update conference call on Thursday, August 12, 2021.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and PeptiDream, Inc. (Tokyo Stock Exchange: 4587), announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today.

GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

CTI BioPharma Corp. announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets.